Vericel (VCEL) Amortizatization of Intangibles (2018 - 2026)
Vericel recorded quarterly Amortizatization of Intangibles of $27000.0 in Q1 2026, down 99.47% quarter-over-quarter from $5.1 million in Q4 2025, and down 98.05% year-over-year from $1.4 million in Q1 2025.
Vericel's Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $27000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 98.05% year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $4.0 million (down 49.63% YoY), while the FY2025 annual figure was $5.4 million, down 19.56% from the prior year.
- Amortizatization of Intangibles came in at $27000.0 for Q1 2026 at Vericel, down from $5.1 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $6.1 million in Q4 2024 to a low of -$1.2 million in Q2 2025.
- A 5-year average of $1.3 million and a median of $965000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 1254.9% in 2025 and fell as far as 560.08% in 2025.
- Vericel's Amortizatization of Intangibles stood at $1.1 million in 2022, then surged by 61.43% to $1.8 million in 2023, then soared by 243.4% to $6.1 million in 2024, then retreated by 16.39% to $5.1 million in 2025, then sank by 99.47% to $27000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $27000.0, $5.1 million, and $70000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | 27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 5.11 Mn |
| Dec 31, 2025 | 5.11 Mn |
| Sep 30, 2025 | 70,000.00 |
| Sep 30, 2025 | 70,000.00 |
| Jun 30, 2025 | -1.21 Mn |
| Jun 30, 2025 | -1.21 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 6.11 Mn |
| Dec 31, 2024 | 6.11 Mn |
| Sep 30, 2024 | 177,000.00 |
| Sep 30, 2024 | 177,000.00 |
| Jun 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 263,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Dec 31, 2023 | 1.78 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 3.79 Mn |
| Sep 30, 2023 | 3.79 Mn |
| Jun 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 214,000.00 |
| Mar 31, 2023 | 290,000.00 |
| Mar 31, 2023 | 290,000.00 |
| Dec 31, 2022 | 1.10 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 965,000.00 |
| Sep 30, 2022 | 965,000.00 |
| Jun 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | -212,000.00 |
| Dec 31, 2021 | -212,000.00 |
| Sep 30, 2021 | -232,000.00 |
| Sep 30, 2021 | -232,000.00 |
| Jun 30, 2021 | -232,000.00 |
| Jun 30, 2021 | -232,000.00 |
| Mar 31, 2021 | -273,000.00 |
| Mar 31, 2021 | -273,000.00 |
| Dec 31, 2020 | 4.47 Mn |
| Dec 31, 2020 | 4.47 Mn |
| Sep 30, 2020 | -1.63 Mn |
| Sep 30, 2020 | -1.63 Mn |
| Jun 30, 2020 | 1.58 Mn |
| Jun 30, 2020 | 1.58 Mn |
| Mar 31, 2020 | 20,000.00 |
| Mar 31, 2020 | 20,000.00 |
| Dec 31, 2019 | -1.40 Mn |
| Dec 31, 2019 | -1.40 Mn |
| Sep 30, 2019 | 1.60 Mn |
| Sep 30, 2019 | 1.60 Mn |
| Jun 30, 2019 | 21,000.00 |
| Jun 30, 2019 | 21,000.00 |
| Mar 31, 2019 | 387,000.00 |
| Mar 31, 2019 | 387,000.00 |
| Dec 31, 2018 | 327,000.00 |
| Dec 31, 2018 | 327,000.00 |